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Cardiac hypertrophyMicro RNAs are small, non-coding RNA molecules that regulate gene expression via either translational
inhibition or mRNA degredation. Enhancer of zeste homolog 2 (EZH2)-mediated hypertrophic signaling
is a major regulatory response to hypertrophic stimuli. In this study, we constructed AAC rat models
and PE-induced hypertrophic cardiomyocytes. We demonstrated that miR-214 relative levels were
upregulated, whereas EZH2 was downregulated in both vivo and vitro models. Further, one conserved
base-pairing site in the EZH2 30-untranslated region (UTR) was veriﬁed. Mutation of the site in the
EZH2 30-UTR completely blocked the negative effect of miR-214 on EZH2, suggesting that EZH2 is a direct
target for miR-214 regulation. Using a gain-of-function approach, incorporating the lentivirus con-
structed miR-214 and its sponge, we demonstrated that miR-214 signiﬁcantly regulated endogenous lev-
els of EZH2 gene expression; whereas, changes in the expression of the Sine oculis homeobox homolog
gene were induced by an adrenergic receptor agonist in the AAC rat model. Having made this study it
is possible to conclude that the negative regulation of EZH2 expression contributed to miR-214-mediated
cardiac hypertrophy.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction major histone methyltransferase of Polycomb repressor complexThe heart responds to physiological stimuli, tissue injury and
endocrine disorders by undergoing hypertrophic growth to sustain
cardiac output [1–3]. Cardiac hypertrophy is initially a functional,
adaptive response, but prolonged hypertrophy can lead to heart
failure, which is one of the major causes of human death around
the world [4]. Cardiac hypertrophy occurs when numerous signal-
ling pathways merge, culminating in well-described transcrip-
tional networks [5–8]. Epigenetic regulation via histone
methylation stabilizes transcriptional programs in embryonic pro-
genitors and their differentiated descendants. This regulation is
likely to be crucial in establishing and maintaining gene expression
and stress responses throughout life. Polycomb complexes might
be used to stabilise cardiac gene expression, as they control cell
identity and epigenetic memory in other systems [9]. Ezh2, the2 (PRC2), trimethylates histone H3 at lysine 27. Stable Ezh2-med-
iated repression of Six1 in differentiating embryonic cardiac pro-
genitors is essential for normal cardiac growth and for stress
responsiveness in adults. Ezh2 modulates a feed-forward pathway
that represses fetal gene expression and that is reinforced by
repression of Six1 [10].
Recently, a new gene regulator, microRNA (miRNA), was identi-
ﬁed as playing an important role in heart disease, including the
stimulation of cardiac hypertrophy. miRNAs are a class of con-
served, single-stranded, non-coding RNAs and consist of 18–25
nucleotides [11,12]. They negatively regulate target gene expres-
sion through mRNA cleavage or translation repression. Cardiac-
speciﬁc deletion of an RNase III endonuclease Dicer, which is
essential for miRNA maturation, induced sudden death and mild
cardiac remodeling in juvenile mice, and produced cardiac dys-
function in adult mice, along with the induction of hypertrophic
marker genes [13]. Recent studies have also indicated that several
miRNAs, including miR-133 [14–19], miR-208 [20,21] and miR-18
[22], actively participate in cardiomyocyte hypertrophy. These
miRNAs are supposed to regulate cardiac hypertrophy by control-
ling cardiac growth, conduction and calcium-dependent signaling.
In addition, miR-214 was also proven to upregulate miRNA in
hypertrophy during several miRNA array tests [10,23,24]. A recent
study discovered a potential regulatory role for micro-RNA-214
(miR-214) in cardiac hypertrophy. It was demonstrated that an
overexpression of miR-214 resulted in pathological cardiac growth
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cal miR-214 signaling of cardiac hypertrophy has still not been
elucidated.
In this study, we explored the relationship between miR-214
and the EZH2-dependent signaling pathway. This study demon-
strated that EZH2 levels were negatively regulated by miR-214.
Treatment with miR-214 resulted in striking decreases in EZH2
mRNA and protein expression, coincident with increases in cardio-
myocyte hypertrophy, which was induced by the application of an
adrenergic receptor agonist. We suggest that silencing of EZH2,
which stimulates Six1, could be one of the miR-214-mediated
mechanisms that provoke cardiac hypertrophy.
2. Materials and methods
2.1. Construction of plasmids and site-directed mutagenesis
The precursor sequence for miR-214 was ampliﬁed by PCR
using human genomic DNA as a template, and the PCR products
were cloned into the pGL3-promoter vector (Invitrogen) to gener-
ate miRNA expression plasmids. For the construction of the lucifer-
ase reporter plasmid, the full-length 30-UTR of EZH2 was ampliﬁed
from rat genomic DNA by PCR and was inserted into the 30-UTR of
the ﬁreﬂy luciferase gene. The mutated 30-UTR luciferase reporter
plasmids were generated by site-directed mutagenesis using plat-
inum Taq DNA Polymerase High Fidelity, according to the manu-
facturer’s instructions (Invitrogen).
2.2. Luciferase assay
HEK293T cells were transfected with luciferase reporter plas-
mids and the miRNA expression plasmid, and a Renilla luciferase
plasmid was cotransfected as an internal control. Cells were har-
vested 24 h after transfection. Luciferase activity was measured
with a dual luciferase reporter assay kit (Promega) on a lumino-
meter [19], as described previously.
2.3. Western blot analysis
Western blotting was performed. Protein lysates were run on
SDS–PAGE gels and transferred to PVDF membranes [15,26,27].
Antibodies against EZH2 and Six1 were purchased from Abcam
Co. Antibody against GAPDH was obtained from CST Co.
2.4. Rat cardiac hypertrophy model
Left-ventricle hypertrophy was induced in 150- to 180-g male
Sprague–Dawley rats by abdominal aorta constriction (AAC), as de-
scribed previously [16]. Brieﬂy, the rats were temporarily anesthe-
tized with chloral hydrate (0.2 mg/g), followed by exposure of the
abdomen, and then the suprarenal abdominal aorta was isolated
and tightened with a 4-0 nylon suture against a 24-gauge needle.
After removing the needle, the incision was closed. A control group
underwent a sham operation involving all the procedures except
for aorta constriction. After surgery, each rat was administered
penicillin twice daily for the ﬁrst 3 days. The rats were sacriﬁced
21 days after surgery [28]. All of the animal protocols were ap-
proved by the Institute of Health Sciences Institutional Animal Care
and Use Committee.
2.5. Cardiomyocyte immunochemistry and cell surface area analysis
Cells were ﬁxed in 4% paraformaldehyde for 15 min and perme-
abilized with 0.1% Triton X-100 in PBS, followed by blocking with
5% goat serum in PBS for 1 h at room temperature. The cells werethen incubated with anti-actinin antibody (Epitomics) at a 1:250
dilution overnight. After washing with PBS three times, the second
antibody, coupled with Alexa Fluor 488 donkey (Invitrogen), was
added to the cells. The nuclei were stained with propidium iodide
(PI). After washing, the slides were mounted using a ﬂuorescent
mounting medium. Cell surface area was analyzed using Image-
Pro Plus software (Media Cybernetics). Images were obtained using
an Leica confocal microscope (CTR MIC) [29].
2.6. Statistical analysis
All of the experiments were performed at least three times. The
data are expressed as means ± SEMs and were analyzed by ANOVA
and post hoc analysis or by t-test as appropriate. A p value of 0.05
or less was considered signiﬁcant [30,31].
3. Results
3.1. EZH2 is decreased in hypertrophic rat hearts and in PE-induced
hypertrophic cardiomyocytes
Previous studies have linked miR-214 to cardiac hypertrophy,
and the expression level of miR-214 was dynamically and inconsis-
tently regulated during the early process [10,23,24]. To address
this issue, we veriﬁed the changes in cardiac miR-214 expression
in a SD rat cardiac hypertrophy model generated by abdominal
aorta constriction (AAC). After constriction for 21 days, the ratio
of heart weight to body weight was signiﬁcantly increased, and
the hearts showed apparent hypertrophic growth, compared with
the hearts of the sham-operated rats (Fig. 1A and B). Several hyper-
trophic markers, including the b-myosin heavy chain (Myh7), skel-
etal muscle a-actin (Acta1) and atrial natriuretic peptide (Nppa),
were also examined. As expected, Acta1, Myh7 and Nppa were
upregulated (Fig. 1C). Using real-time PCR analysis, the level of
miR-214 in the hypertrophic left ventricle was increased by
160%, compared with levels in the sham controls (Fig. 1D). To
investigate whether the repression of EZH2 by miR-214 played a
pathological role in this process, we detected the expression of
EZH2 in hypertrophic left ventricles. Real-time PCR analysis
showed that the mRNA level of EZH2 was decreased (P < 0.05,
Fig. 1E). Additionally, the protein level of EZH2 was decreased as
determined by western blot analysis (Fig. 1F). In addition this,
we induced primary cultured neonatal rat cardiomyocyte hyper-
trophy in vitro by stimulation with phenylephrine (PE). After 48 h
of treatment, the cardiomyocytes developed hypertrophy, evi-
denced by their increased cell surface area (Fig. 2A and B). Real-
time PCR analysis revealed that the expression of miR-214 in
hypertrophic cardiomyocytes was increased by 130% compared
to that in the controls (P < 0.05; Fig. 2C). In agreement with the in-
crease in miR-214, the endogenous EZH2 protein level was down-
regulated in PE-induced hypertrophic cardiomyocytes (Fig. 2D).
These results suggest that EZH2 was derepressed by miR-214 dur-
ing the pathogenesis of cardiac hypertrophy.
3.2. MiR-214 targets the 30-UTR of EZH2
We validated the miRNA-mRNA hybridization structures and
free energies between microRNA seed sequences and mRNA se-
quences by RNAhybrid. The EZH2 30 UTR mutant had 3 different
bases, which are C–G,G–A,C–A (Fig. 3A). The chimeric vector, lucif-
erase-EZH2 30-UTR, carries a constitutively activated promoter,
which can express luciferase as a reporter (Fig. 3B). The effect of
miR-214 on luciferase expression can be represented by the
changes in luciferase activity. We co-transfected this vector with
the miR-214 mimic into myogenic 293T cells. As indicated in
Fig. 3C, the introduction of miR-214 mimic decreased luciferase
Fig. 1. EZH2 is decreased in hypertrophic rat hearts in contrast to upregulation of miR-214. SD rats were subjected to sham operations or AAC for 21 days, and then their
hearts were analyzed. (A) Representative hearts from rats after sham operation or AAC. Scale bar: 10 lm. (B) Heart weight-to-body weight ratio of SD rats (n = 8) was
signiﬁcantly greater than that of controls (n = 8). (C) Real-time PCR analysis of the expression of Acta1, Myh7, and Nppa in sham and AAC rat hearts (n = 8 for sham group;
n = 8 for AAC group). (D) The expression of miR-214 level was obviously increased in AAC rat hearts. (E) The mRNA level of EZH2 was downregulated in AAC rat hearts. (F)
EZH2 was also downregulated as determined by western blot analysis and semiquantiﬁed by Image J in each group. The data shown represent three independent
experiments. ⁄P < 0.05 vs. sham; ⁄⁄P < 0.01 vs. sham.
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Fig. 2. EZH2 is downregulated in hypertrophic cardiomyocytes. (A) a-actinin staining shows hypertrophy of neonatal cardiomyocytes treated with 100 lM phenylephrine
(PE) for 48 h. Representative confocal images are shown. Scale bar: 10 lm. (B) Quantitative analysis of cardiomyocyte size. Approximately 200 cells immunostained with anti-
a-actinin antibody were randomly chosen from each treatment for surface area measurement. (C) The expression level of miR-214 was increased in PE-treated
cardiomyocytes analyzed by real-time PCR. (D) EZH2 was downregulated in PE-induced hypertrophic cardiomyocytes as determined by western blot analysis and
semiquantiﬁed. ⁄P < 0.05 vs. control.
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mic (P < 0.05). In a parallel experiment, the inhibitory effect of
miR-214 on cells transfected with the mutant reporter vector
(the putative 30 UTR targeting site was mutated) was completely
eliminated, as evidenced by high luciferase activity (Fig. 3C). These
results conﬁrmed the bioinformatics prediction that the 30-UTR of
EZH2 would be targeted by miR-214.
3.3. Overexpression of miR-214 by infection with lentivirus induces
cardiomyocyte hypertrophy
To investigate the possible effects of miR-214 on cardiomyocyte
hypertrophy, we infected neonatal rat cardiomyocytes with Lenti-
miR-214 and examined the miR-214 expression levels. The Lenti-
vector was used as a control. The infection of cardiomyocytes with
Lenti-miR-214 induced a 33-fold increase in miR-214 over the
endogenous level, as determined by real-time PCR analysis
(Fig. 4A). To test further whether the increase in miR-214 wassufﬁcient to induce cardiac hypertrophy, we constructed a lentivi-
rus overexpressing miR-214 (Lenti-miR-214) and infected the neo-
natal cardiomyocytes. After infection for 72 h, the cell size, as
measured by cell surface area, was increased with Lenti-miR-214
infection compared with Lenti-vector infection. Overexpression of
miR-214 induced an the increase in cell size as measured by cell
surface area (Fig. 4B and C). These results indicate that miR-214
overexpression in cardiomyocytes affects the morphology and
structure of the cells, perhaps through the regulation of the cyto-
skeleton. To determine the effect of miR-214 overexpression on
hypertrophic cardiomyocytes at the molecular level, the hypertro-
phic markers Acta1, Myh7 and Nppa were examined. Expression of
all these genes was signiﬁcantly increased in Lenti-miR-214-in-
fected cells (Fig. 4D). These results indicate that miR-214 overex-
pression could result in cardiomyocyte hypertrophy. To establish
whether the silencing of endogenous miR-214 would impair
hypertrophy in vitro, we generated a Lentiviral vector in which a
30-UTR with tandem miR-214-binding sites was linked to the
Fig. 3. Analysis of the EZH2 30-UTR by luciferase activity assay. (A) Alignment of rat miR-214 sequence with the 30-UTRs of EZH2 among different species. The absolute
position of the miR-214 binding site in rat EZH2 mRNA and EZH2 30-UTR mutant are shown. MBS:miR-214 binding site. (B) Luciferase-EZH2 30-UTR carries pGL3-promoter
vector. (C) Addition of the miR-214 mimic attenuated EZH2 30-UTR reporter gene activity. Mutation of miR-214 putative target site blocked the suppressive effect of miR-214
on the target, suggesting EZH2 as a miR-214 target gene. ⁄P < 0.05 vs. control mimic.
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plementary sequence acts as a sponge to sequester endogenous
miR-214. Infection of Lenti-sponge (Lenti-spg) silenced miR-214.
Neonatal cardiomyocytes were infected with Lenti-miR-214 or
Lenti-vector for 72 h, followed by treatment with PE for an addi-
tional 48 h. This demonstrated that miR-214 decreased 7-fold with
the infection of Lenti-spg (Fig. 4E). Importantly, infection with Len-
ti-spg signiﬁcantly reduced the cell size by PE stimulation (Fig. 4F
and G) and inhibited the expression of hypertrophic markers
(Fig. 4H). These results indicate that silencing of endogenous
miR-214 upregulated the expression of EZH2 and attenuated car-
diomyocyte hypertrophy. Collectively, these results suggest that
elevated levels of miR-214 induced cardiac hypertrophy. However,
blocking the function of miR-214 directly inhibited cardiac hyper-
trophy, which might have occurred through derepression of EZH2.
Our results thus support the notion that miR-214 would induce
hypertrophic activity.
4. Discussion
It is generally believed that there is an urgent need to develop
effective, targeted therapeutic strategies to increase the survivalrate for patients with cardiac hypertrophy, which is the most com-
mon cause of heart failure [10,32]. Thus, identiﬁcation of the
molecular pathogenesis of cardiac hypertrophy is crucial. Recently,
an increasing number of studies have demonstrated that post-tran-
scription regulation of miRNAs frequently occurs in cardiac tissues.
Experimental evidence has demonstrated that miRNAs would be
ideal biomarkers or therapeutic targets [33]. Previous studies have
also found that upregulated miRNAs are common in cardiac hyper-
trophy [20,28]. A number of studies have created signatures for
cardiac hypertrophy, which will help further establish molecular
diagnoses and improve prognosis and therapy using miRNAs. How-
ever, only a limited number of studies have explored the modula-
tory function of miRNAs in cardiac hypertrophy. The roles of
speciﬁc miRNAs in cardiac hypertrophy are still poorly understood.
It is noteworthy that miR-214 is frequently upregulated in pres-
sure-overloaded hypertrophic hearts. Recent studies have also
demonstrated that miR-214 displays obvious myocardial expres-
sion during heart development. However, miR-214 function in car-
diac hypertrophy has not yet been elucidated. In this study, we
investigated the physiological functions of miR-214 and the molec-
ular mechanisms by which miR-214 induces cardiac hypertrophy.
The physiological and pathological consequences of miR-214 were
Fig. 4. Effects of overexpression or knockdown of miR-214 on cardiomyocytes.
Cardiomyocytes were infected with recombinant Lentivirus expressing miR-214
(Lenti-miR-214) or with an empty vector (Lenti-vector) for 72 h. (A) Overexpression
of miR-214 in neonatal rat cardiomyocytes signiﬁcantly increased expression of
miR-214. (B) Lenti-miR-214 increased cell size vs. Lenti-vector. Representative
confocal images of a-actinin immunostaining are shown. Scale bar: 10 lm. (C)
Quantitative analysis of cardiomyocyte size. (D) miR-214 provoked the expression
of the indicated hypertrophic markers in neonatal rat cardiomyocytes by real-time
PCR analysis. Neonatal rat cardiomyocytes were infected with recombinant
Lentivirus, expressing miR-214 sponge (Lenti-spg) or Lenti-vector, for 72 h and
were treated with 100 lM PE for additional 48 h; then, the cells were analyzed. (E)
Repression of miR-214 in neonatal rat cardiomyocytes signiﬁcantly decreased
expression of miR-214. (F) a-actinin staining of PE-treated neonatal rat cardio-
myocytes indicated that the cell size of Lenti-spg infected cardiomyocytes was
reduced. Representative images were obtained by confocal microscope. Scale bar:
10 lm. (G) Quantitative analysis of cardiomyocyte size. (H) The expression of the
indicated hypertrophic markers was downregulated in PE-stimulated neonatal rat
cardiomyocytes infected with Lenti-spg, compared with cells infected with Lenti-
vector by real-time PCR analysis. ⁄⁄P < 0.01 vs. Lenti-vector.
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loss-of-function approaches. Most importantly, we performedcurative experiments to demonstrate that miR-214 inhibition
was indeed beneﬁcial for pressure overload-induced cardiac
hypertrophy and HF. Previous studies have revealed that a limited
number of miRNAs could constitute new therapeutic targets for
ischemic heart diseases [34–38], as well as hypertension-induced
HF [22,32,39–41]. Our study showed that knockdown of miR-214
by Lentivirus signiﬁcantly attenuated hypertrophic effects caused
by pressure overload, providing a new therapeutic target for pres-
sure overload heart diseases.
In this study, we identiﬁed that EZH2 was the target of miR-214
and of the partially mediated cardiac hypertrophy that resulted
frommiR-214 overexpression. Six1 is a well-known critical regula-
tor during cardiac hypertrophy. MiR-214 sponge inhibits mechan-
ical stress-induced hypertrophy of cultured neonatal rat
ventricular cardiomyocytes. Cardiac hypertrophy, induced by pres-
sure overload in heterozygous EZH2-deﬁcient mice, is slightly
more pronounced than in wild-type controls. Studies in cardiomy-
ocyte-speciﬁc EZH2 knockout mice have shown that EZH2 sup-
presses cardiac growth and embryonic gene expression, at the
same time protecting the heart from oxidative damage. Previous
studies have shown that miR-214 represses transcription of devel-
opmental regulators in embryonic stem (ES) cells and in commit-
ted cell lineages, including skeletal muscle cells (SMC), by
targeting EZH2 [42]. In our study, we observed that miR-214 tar-
geted EZH2 in cardiomyocytes. These ﬁndings are corroborated
by the signiﬁcant downregulation of EZH2 expression in the
293T cells of co-transfected miR-214, further conﬁrmed by the
Lentivirus experiment, which showed that overexpression of
miR-214 increased hypertrophic growth. As miR-214 might target
hundreds of mRNAs simultaneously, our results demonstrate that
EZH2 is an important, but possibly not the only, target gene
responsible for cardiac hypertrophy in miR-214-induced cardiac
hypertrophy.
In conclusion, our study identiﬁed that the miR-214-regulated
EZH2 signaling pathway is a regulator of cardiac hypertrophy, sug-
gesting that antagonizing miR-214 might be a new therapeutic en-
try point for treating cardiac diseases.
Acknowledgments
We are grateful to Dr. Haiyang Xie for valuable help with the
cell and animal experiments and to Dr. Xiaobo Yu for advice on
the statistical analysis. Sources of funding: This study was sup-
ported by a research fund from Zhejiang Natural Science Founda-
tion (Y2100486). The funding agencies had no role in the study
design, data collection and analysis, decision to publish, or prepa-
ration of the manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bbrc.2013.05.079.
References
[1] J. Fiedler, T. Thum, MicroRNAs in Myocardial Infarction, Arterios. Thromb. Vas.
Biol. 33 (2) (2013) 201–205.
[2] Y.R. Fujii, The xenotropic microRNA gene information for stem cell researches
and clinical applications (2013).
[3] P. Kathirvel, G. Ramesh Kumar, K. Sankaranarayanan, A computational
prediction of conserved microRNA targets of ion channels in vertebrates,
Curr. Bioinform. 8 (1) (2013) 93–111.
[4] L. Vincenzo, C. Ventura, Regenerative medicine approach to repair the failing
heart, Vas. pharmacol. (2013).
[5] P. Roche, M.P. Czubryt, J.T. Wigle, Molecular mechanisms of cardiac
development, Car. Adapt. (2013) 19–39.
[6] L. Shijun, M. Ding’an, MicroRNAs and cardiovascular disease, Int. J. Pathol. Clin.
Med. 6 (2011) 017.
584 T. Yang et al. / Biochemical and Biophysical Research Communications 436 (2013) 578–584[7] B.L. Stauffer, G. Russell, K. Nunley, S.D. Miyamoto, C.C. Sucharov, MiRNA
expression in pediatric failing human heart, J. Mol. Cell. Cardiol. (2013).
[8] C. Vacchi-Suzzi, F. Hahne, P. Scheubel, M. Marcellin, V. Dubost, M. Westphal, C.
Boeglen, S. Büchmann-Møller, M.S. Cheung, A. Cordier, Heart structure-speciﬁc
transcriptomic atlas reveals conserved microRNA–mRNA interactions, PLoS
One 8 (1) (2013) e52442.
[9] S. Ryu, K. McDonnell, H. Choi, D. Gao, M. Hahn, N. Joshi, S. Park, R. Catena, Y. Do,
J. Brazin, Suppression of miRNA-708 by polycomb group promotes metastases
by calcium-induced cell migration, Cancer Cell 23 (1) (2013) 63.
[10] P. Delgado-Olguín, Y. Huang, X. Li, D. Christodoulou, C.E. Seidman, J. Seidman,
A. Tarakhovsky, B.G. Bruneau, Epigenetic repression of cardiac progenitor gene
expression by Ezh2 is required for postnatal cardiac homeostasis, Nat. Gene.
(2012).
[11] V. Di Stefano, G. Zaccagnini, M.C. Capogrossi, F. Martelli, MicroRNAs as
peripheral blood biomarkers of cardiovascular disease, Vas. Pharmacol. 55 (4)
(2011) 111–118.
[12] T. Kinoshita, N. Nohata, M. Fuse, T. Hanazawa, N. Kikkawa, L. Fujimura, H.
Takano, Y. Yamada, H. Yoshino, H. Enokida, Tumor suppressive <i> microRNA-
133a/<i> regulates novel targets Moesin contributes to cancer cell
proliferation and invasion in head and neck squamous cell carcinoma,
Biochem. Biophys. Res. Commun. (2012).
[13] J.F. Chen, E.P. Murchison, R. Tang, T.E. Callis, M. Tatsuguchi, Z. Deng, M. Rojas,
S.M. Hammond, M.D. Schneider, C.H. Selzman, Targeted deletion of Dicer in
the heart leads to dilated cardiomyopathy and heart failure, Proc. Natl. Acad.
Sci. 105 (6) (2008) 2111–2116.
[14] A. Care, D. Catalucci, F. Felicetti, D. Bonci, A. Addario, P. Gallo, M.L. Bang, P.
Segnalini, Y. Gu, N.D. Dalton, MicroRNA-133 controls cardiac hypertrophy, Nat.
Med. 13 (5) (2007) 613–618.
[15] F.M. Drawnel, D. Wachten, J.D. Molkentin, M. Maillet, J.M. Aronsen, F. Swift, I.
Sjaastad, N. Liu, D. Catalucci, K. Mikoshiba, Mutual antagonism between IP3RII
and miRNA-133a regulates calcium signals and cardiac hypertrophy, J. General
Physiol. 141 (1) (2013) i1.
[16] R.F. Duisters, A.J. Tijsen, B. Schroen, J.J. Leenders, V. Lentink, I. van der Made, V.
Herias, R.E. van Leeuwen, M.W. Schellings, P. Barenbrug, MiR-133 and miR-30
regulate connective tissue growth factor implications for a role of microRNAs
in myocardial matrix remodeling, Circul. Res. 104 (2) (2009) 170–178.
[17] B. Feng, S. Chen, B. George, Q. Feng, S. Chakrabarti, MiR133a regulates
cardiomyocyte hypertrophy in diabetes, Diab./Metab. Res. Rev. 26 (1) (2010)
40–49.
[18] T. Horie, K. Ono, H. Nishi, Y. Iwanaga, K. Nagao, M. Kinoshita, Y. Kuwabara, R.
Takanabe, K. Hasegawa, T. Kita, MicroRNA-133 regulates the expression of
GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac
myocytes, Biochem. Biophys. Res. Commun. 389 (2) (2009) 315–320.
[19] Q. Li, X. Lin, X. Yang, J. Chang, NFATc4 is negatively regulated in miR-133a-
mediated cardiomyocyte hypertrophic repression, Am. J. Physiol.-Heart Circul.
Physiol. 298 (5) (2010) H1340–H1347.
[20] E. van Rooij, D. Quiat, B.A. Johnson, L.B. Sutherland, X. Qi, J.A. Richardson, R.J.
Kelm, E.N. Olson, A family of microRNAs encoded by myosin genes governs
myosin expression and muscle performance, Develop. Cell 17 (5) (2009) 662–
673.
[21] E. van Rooij, L.B. Sutherland, X. Qi, J.A. Richardson, J. Hill, E.N. Olson, Control of
stress-dependent cardiac growth and gene expression by a microRNA, Sci.
Signal. 316 (5824) (2007) 575.
[22] M. Tatsuguchi, H.Y. Seok, T.E. Callis, J.M. Thomson, J.F. Chen, M. Newman, M.
Rojas, S.M. Hammond, D.Z. Wang, Expression of microRNAs is dynamically
regulated during cardiomyocyte hypertrophy, J. Mol. Cell. Cardiol. 42 (6)
(2007) 1137–1141.
[23] Y. Cheng, R. Ji, J. Yue, J. Yang, X. Liu, H. Chen, D.B. Dean, C. Zhang, MicroRNAs
are aberrantly expressed in hypertrophic heart: do they play a role in cardiac
hypertrophy?, Am J. Pathol. 170 (6) (2007) 1831.
[24] P.A. Costa da Martins, M. Bourajjaj, M. Gladka, M. Kortland, R.J. van Oort, Y.M.
Pinto, J.D. Molkentin, L.J. De Windt, Conditional dicer gene deletion in thepostnatal myocardium provokes spontaneous cardiac remodeling, Circulation
118 (15) (2008) 1567–1576.
[25] E. Van Rooij, L.B. Sutherland, N. Liu, A.H. Williams, J. McAnally, R.D. Gerard, J.A.
Richardson, E.N. Olson, A signature pattern of stress-responsive microRNAs
that can evoke cardiac hypertrophy and heart failure, Proc. Natl. Acad. Sci. 103
(48) (2006) 18255–18260.
[26] W. Pan, Y. Zhong, C. Cheng, B. Liu, L. Wang, A. Li, L. Xiong, S. Liu, MiR-30-
regulated autophagy mediates angiotensin II-induced myocardial
hypertrophy, PLoS One 8 (1) (2013) e53950.
[27] Y. Yang, T. Ago, P. Zhai, M. Abdellatif, J. Sadoshima, Thioredoxin 1 negatively
regulates angiotensin II–induced cardiac hypertrophy through upregulation
of miR-98/let-7 novelty and signiﬁcance, Circul. Res. 108 (3) (2011) 305–
313.
[28] J. Wang, Y. Song, Y. Zhang, H. Xiao, Q. Sun, N. Hou, S. Guo, Y. Wang, K. Fan, D.
Zhan, Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy
and dysfunction in mice, Cell Res. 22 (3) (2011) 516–527.
[29] Z. Lin, I. Murtaza, K. Wang, J. Jiao, J. Gao, P.F. Li, MiR-23a functions downstream
of NFATc3 to regulate cardiac hypertrophy, Proc. Natl. Acad. Sci. 106 (29)
(2009) 12103–12108.
[30] W. Townley-Tilson, T.E. Callis, D.Z. Wang, MicroRNAs 1, 133, and 206: critical
factors of skeletal and cardiac muscle development, function, and disease, Int.
J. Biochem. Cell Biol. 42 (8) (2010) 1252–1255.
[31] F. Varrone, B. Gargano, P. Carullo, D. Di Silvestre, A. De Palma, L. Grasso, C. Di
Somma, P. Mauri, L. Benazzi, A. Franzone, The circulating level of FABP3 is
an indirect biomarker of microRNA-1, J. Am. College Cardiol. 61 (1) (2013)
88–95.
[32] J. Wang, R. Xu, F. Lin, S. Zhang, G. Zhang, S. Hu, Z. Zheng, MicroRNA: novel
regulators involved in the remodeling and reverse remodeling of the heart,
Cardiology 113 (2) (2009) 81–88.
[33] J. Song, M. Lee, D. Kim, J. Han, C. Chun, E. Jin, MicroRNA-181b regulates
articular chondrocytes differentiation and cartilage integrity, Biochem.
Biophys. Res. Commun. (2013).
[34] H. Funahashi, H. Izawa, A. Hirashiki, X.W. Cheng, Y. Inden, M. Nomura, T.
Murohara, Altered microRNA expression associated with reduced
catecholamine sensitivity in patients with chronic heart failure, J. Cardiol. 57
(3) (2011) 338–344.
[35] S. Ikeda, S.W. Kong, J. Lu, E. Bisping, H. Zhang, P.D. Allen, T.R. Golub, B. Pieske,
W.T. Pu, Altered microRNA expression in human heart disease, Physiol. Gen.
31 (3) (2007) 367–373.
[36] S. Li, J. Zhu, W. Zhang, Y. Chen, K. Zhang, L.M. Popescu, X. Ma, W.B. Lau, R. Rong,
X. Yu, Signature microRNA expression proﬁle of essential hypertension and its
novel link to human cytomegalovirus infection clinical perspective, Circulation
124 (2) (2011) 175–184.
[37] D. Sayed, C. Hong, I.Y. Chen, J. Lypowy, M. Abdellatif, MicroRNAs play an
essential role in the development of cardiac hypertrophy, Circul. Res. 100 (3)
(2007) 416–424.
[38] U.P.R. Soci, T. Fernandes, N.Y. Hashimoto, G.F. Mota, M.A. Amadeu, K.T. Rosa,
M.C. Irigoyen, M.I. Phillips, E.M. Oliveira, MicroRNAs 29 are involved in the
improvement of ventricular compliance promoted by aerobic exercise training
in rats, Physiol. Gen. 43 (11) (2011) 665–673.
[39] T. Thum, D. Catalucci, J. Bauersachs, MicroRNAs: novel regulators in cardiac
development and disease, Cardiovas. Res. 79 (4) (2008) 562–570.
[40] K.D. Wilson, S. Hu, S. Venkatasubrahmanyam, J.D. Fu, N. Sun, O.J. Abilez, J.J.A.
Baugh, F. Jia, Z. Ghosh, R.A. Li, Dynamic microRNA expression programs during
cardiac differentiation of human embryonic stem cells clinical perspective role
for miR-499, Circul. Cardiovas. Gene. 3 (5) (2010) 426–435.
[41] K.C. Yang, Y.C. Ku, M. Lovett, J.M. Nerbonne, Combined deep microRNA and
mRNA sequencing identiﬁes protective transcriptomal signature of enhanced
PI3Ka signaling in cardiac hypertrophy, J. Mol. Cell. Cardiol. (2012).
[42] A.H. Juan, R.M. Kumar, J.G. Marx, R.A. Young, V. Sartorelli, Mir-214-dependent
regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic
stem cells, Mol. Cell 36 (1) (2009) 61–74.
